Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
-
Published:2023-03
Issue:
Volume:29
Page:101624
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Yu Minghui,
Liang Yangyueying,
Li LonghuiORCID,
Zhao Lu,
Kong Fanming
Subject
Cancer Research,Oncology
Reference63 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021
2. The world cancer research fund/american institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions;Clinton;J. Nutr.,2020
3. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann. Oncol.,2008
4. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab;Tanner;Ann. Oncol.,2005
5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献